Changzhou Qianhong Biopharma Co Ltd (002550) - Total Assets
Based on the latest financial reports, Changzhou Qianhong Biopharma Co Ltd (002550) holds total assets worth CN¥3.23 Billion CNY (≈ $472.92 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Changzhou Qianhong Biopharma Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 002550 market cap for the company's overall valuation and market capitalisation.
Changzhou Qianhong Biopharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Changzhou Qianhong Biopharma Co Ltd's total assets of CN¥3.23 Billion consist of 61.8% current assets and 38.2% non-current assets. Review how much debt does Changzhou Qianhong Biopharma Co Ltd carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.9% |
| Accounts Receivable | CN¥257.33 Million | 8.3% |
| Inventory | CN¥372.44 Million | 12.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥261.42 Million | 8.5% |
| Goodwill | CN¥11.14 Million | 0.4% |
Asset Composition Trend (2007–2025)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Changzhou Qianhong Biopharma Co Ltd (002550) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Changzhou Qianhong Biopharma Co Ltd's current assets represent 61.8% of total assets in 2025, a decrease from 65.1% in 2007.
- Cash Position: Cash and equivalents constituted 15.9% of total assets in 2025, down from 29.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 4.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 12.1% of total assets.
Changzhou Qianhong Biopharma Co Ltd Competitors by Total Assets
Key competitors of Changzhou Qianhong Biopharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Changzhou Qianhong Biopharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.30 | 10.22 | 9.35 |
| Quick Ratio | 5.84 | 8.20 | 6.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.75 Billion | CN¥1.68 Billion | CN¥1.23 Billion |
Changzhou Qianhong Biopharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Changzhou Qianhong Biopharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.18 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 9.1% |
| Total Assets | CN¥3.09 Billion |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Changzhou Qianhong Biopharma Co Ltd's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Changzhou Qianhong Biopharma Co Ltd's assets grew by 9.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Changzhou Qianhong Biopharma Co Ltd (2007–2025)
The table below shows the annual total assets of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.09 Billion ≈ $451.70 Million |
+9.06% |
| 2024-12-31 | CN¥2.83 Billion ≈ $414.18 Million |
+2.33% |
| 2023-12-31 | CN¥2.77 Billion ≈ $404.76 Million |
-1.42% |
| 2022-12-31 | CN¥2.81 Billion ≈ $410.60 Million |
+11.86% |
| 2021-12-31 | CN¥2.51 Billion ≈ $367.06 Million |
+2.31% |
| 2020-12-31 | CN¥2.45 Billion ≈ $358.77 Million |
-16.44% |
| 2019-12-31 | CN¥2.93 Billion ≈ $429.38 Million |
-7.68% |
| 2018-12-31 | CN¥3.18 Billion ≈ $465.09 Million |
+4.40% |
| 2017-12-31 | CN¥3.04 Billion ≈ $445.48 Million |
+0.34% |
| 2016-12-31 | CN¥3.03 Billion ≈ $443.95 Million |
+7.09% |
| 2015-12-31 | CN¥2.83 Billion ≈ $414.58 Million |
+22.61% |
| 2014-12-31 | CN¥2.31 Billion ≈ $338.13 Million |
+11.83% |
| 2013-12-31 | CN¥2.07 Billion ≈ $302.36 Million |
+7.21% |
| 2012-12-31 | CN¥1.93 Billion ≈ $282.04 Million |
+4.00% |
| 2011-12-31 | CN¥1.85 Billion ≈ $271.18 Million |
+237.85% |
| 2010-12-31 | CN¥548.53 Million ≈ $80.27 Million |
+2.75% |
| 2009-12-31 | CN¥533.87 Million ≈ $78.12 Million |
+36.28% |
| 2008-12-31 | CN¥391.74 Million ≈ $57.32 Million |
+35.76% |
| 2007-12-31 | CN¥288.56 Million ≈ $42.23 Million |
-- |
About Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more